Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ... of the Society for Neuro-Oncology (SNO ...

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta ... of the Society for Neuro-Oncology (SNO ...

Benzinga Neuro, our in-house GPT-4-based content generation system, exploits the extensive Benzinga Ecosystem, including native data, APIs and more to create comprehensive and timely stories for you.

INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming plenary oral presentation at the 29 th Annual Meeting and Education ...

Today, we put medical device concern ClearPoint Neuro in the spotlight. ClearPoint's stock has approximately doubled since its Q2 earnings report, and investors seem enamored with its 'milestone ...

'Neuro AI is our flagship AI platform,' Hodjat tells CRN. ‘We use it to develop decision-making use cases for our clients. Now we've made it agent-based. It’s a multi-agent-based system with ...

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) ...

Gen Alpha, or those born after 2010, have developed their own terminology from 'skibidi' to 'fanum tax' Getty Gen Alpha have their own grasp on vocabulary that elder generations may call "sus ...

An international research team co-led by Los Alamos National Laboratory observed ultrahigh-energy gamma rays at more than 100 teraelectron volts, tracking their origin to the galactic center for ...